2017
Predictors of Waitlist Mortality in Portopulmonary Hypertension
DuBrock HM, Goldberg DS, Sussman NL, Bartolome SD, Kadry Z, Salgia RJ, Mulligan DC, Kremers WK, Kawut SM, Krowka MJ, Channick RN. Predictors of Waitlist Mortality in Portopulmonary Hypertension. Transplantation 2017, 101: 1609-1615. PMID: 28207639, PMCID: PMC5481480, DOI: 10.1097/tp.0000000000001666.Peer-Reviewed Original ResearchMeSH KeywordsArterial PressureCause of DeathChi-Square DistributionDatabases, FactualDecision Support TechniquesFemaleHumansHypertension, PortalHypertension, PulmonaryKaplan-Meier EstimateLiver DiseasesLiver TransplantationMaleMiddle AgedMultivariate AnalysisPortal PressurePredictive Value of TestsProportional Hazards ModelsPulmonary ArteryPulmonary CirculationRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTissue and Organ ProcurementTreatment OutcomeVascular ResistanceWaiting ListsConceptsPortopulmonary hypertensionWaitlist mortalityMELD exceptionsLiver diseaseException scoreEnd-Stage Liver Disease (MELD) exception pointsSignificant predictorsCox proportional hazards modelMELD exception scoreWaitlist mortality riskRetrospective cohort studyPulmonary arterial pressureTransplantation Network databaseSignificant univariate predictorsOnly significant univariate predictorsProportional hazards modelMELD scorePosttransplant mortalityPulmonary hypertensionCohort studyArterial pressureUnivariate predictorsC-statisticMortality riskHazards model
2016
Predicting Outcomes on the Liver Transplant Waiting List in the United States
Hart A, Schladt DP, Zeglin J, Pyke J, Kim WR, Lake JR, Roberts JP, Hirose R, Mulligan DC, Kasiske BL, Snyder JJ, Israni AK. Predicting Outcomes on the Liver Transplant Waiting List in the United States. Transplantation 2016, 100: 2153-2159. PMID: 27490411, PMCID: PMC5369025, DOI: 10.1097/tp.0000000000001384.Peer-Reviewed Original ResearchMeSH KeywordsAdultEnd Stage Liver DiseaseHumansLiver TransplantationSeverity of Illness IndexTissue and Organ ProcurementTissue DonorsUnited StatesWaiting ListsConceptsDonation service areaLiver transplantWaiting listEnd-stage liver disease (MELD) scoreLiver transplant waiting listTransplant Recipients databaseLiver Disease scoreMELD exception pointsTransplant waiting listAvailability of organsTransplant probabilityRecipients databasePatient characteristicsScientific RegistryTransplant programsUS adultsDisease scorePredicting OutcomeException pointsTransplantBlood typeOutcomesOngoing disparitiesCorresponding percentilesOnline calculator
2015
Liver allocation: Can we ever get it right and should we ever get it right?
Neuberger J, Mulligan D. Liver allocation: Can we ever get it right and should we ever get it right? Hepatology 2015, 61: 28-31. PMID: 25130673, DOI: 10.1002/hep.27359.Peer-Reviewed Original ResearchCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsLiver TransplantationMaleSeverity of Illness IndexWaiting Lists
2009
Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course
Gallegos‐Orozco J, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transplantation 2009, 15: 1872-1881. PMID: 19938138, DOI: 10.1002/lt.21954.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultBiopsyDisease ProgressionFemaleGraft RejectionHepatitis CHumansKaplan-Meier EstimateLiver CirrhosisLiver FailureLiver TransplantationLiving DonorsMaleMiddle AgedProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeConceptsEnd-stage liver diseaseHCV-positive recipientsLiver transplantHepatocellular carcinomaHCV recurrenceAcute rejectionPatient survivalBiopsy-proven acute rejectionMedian age 53 yearsHistory of HCCAggressive HCV recurrenceEarly acute rejectionProtocol liver biopsiesSignificant HCV recurrenceAdult liver transplantsAdvanced donor ageAge 53 yearsAge 39 yearsDay of transplantationLong-term survivalElectronic medical recordsAvoidance of rejectionEvaluable populationRapid fibrosersHepatitis C
2006
Model for end‐stage liver disease (MELD) exception for portopulmonary hypertension
Krowka MJ, Fallon MB, Mulligan DC, Gish RG. Model for end‐stage liver disease (MELD) exception for portopulmonary hypertension. Liver Transplantation 2006, 12: s114-s116. PMID: 17123283, DOI: 10.1002/lt.20975.Peer-Reviewed Original ResearchModel for end‐stage liver disease (MELD) exception for hepatopulmonary syndrome
Fallon MB, Mulligan DC, Gish RG, Krowka MJ. Model for end‐stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transplantation 2006, 12: s105-s107. PMID: 17123282, DOI: 10.1002/lt.20971.Peer-Reviewed Original ResearchLiver Transplantation in the MELD Era: A Single-Center Experience
Sachdev M, Hernandez JL, Sharma P, Douglas DD, Byrne T, Harrison ME, Mulligan D, Moss A, Reddy K, Vargas HE, Rakela J, Balan V. Liver Transplantation in the MELD Era: A Single-Center Experience. Digestive Diseases And Sciences 2006, 51: 1070-1078. PMID: 16865573, DOI: 10.1007/s10620-006-8011-1.Peer-Reviewed Original ResearchMeSH KeywordsArizonaCarcinoma, HepatocellularFemaleHepatitis CHumansLiver DiseasesLiver NeoplasmsLiver TransplantationMaleMedical RecordsMiddle AgedOutcome Assessment, Health CareResource AllocationRetrospective StudiesRisk AssessmentSeverity of Illness IndexSurvival AnalysisTissue and Organ ProcurementWaiting ListsConceptsDeceased donor liver transplantationLiver transplantationTransplantation ratesEndstage Liver Disease (MELD) scoreImpact of MELDDonor liver transplantationLiver Disease scoreUnderlying liver diseaseSingle-center experienceHepatocellular carcinoma patientsHepatitis C virusNew allocation policyHCC candidatesMELD implementationNew MELDTimely transplantClinical deteriorationMELD eraCarcinoma patientsLiver diseaseHepatitis C virus groupC virusHCC patientsMayo ClinicDropout rate